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Gliomas are the most common malignant brain tumors and account for around 60% of 
all primary central nervous system cancers. Glioblastoma multiforme (GBM) is a grade IV 
glioma associated with a poor outcome despite recent advances in chemotherapy. The 
etiology of gliomas is unknown, but neurotropic viruses including the Epstein–Barr virus 
(EBV) that is transmitted via salivary and genital fluids have been implicated recently. EBV 
is a member of the gamma herpes simplex family of DNA viruses that is known to cause 
infectious mononucleosis (glandular fever) and is strongly linked with the oncogenesis of 
several cancers, including B-cell lymphomas, nasopharyngeal, and gastric carcinomas. 
The fact that EBV is thought to be the causative agent for primary central nervous system 
(CNS) lymphomas in immune-deficient patients has led to its investigations in other brain 
tumors including gliomas. Here, we provide a review of the clinical literature pertaining to 
EBV in gliomas and discuss the possibilities of this virus being simply associative, caus-
ative, or even an experimental artifact. We searched the PubMed/MEDLINE databases 
using the following key words such as: glioma(s), glioblastoma multiforme, brain tumors/
cancers, EBV, and neurotropic viruses. Our literature analysis indicates conflicting results 
on the presence and role of EBV in gliomas. Further comprehensive studies are needed 
to fully implicate EBV in gliomagenesis and oncomodulation. Understanding the role of 
EBV and other oncoviruses in the etiology of gliomas, would likely open up new avenues 
for the treatment and management of these, often fatal, CNS tumors.
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iNTRODUCTiON
Gliomas and Glioblastoma Multiforme (GM)
Gliomas (glial tumors) are the most common malignant brain tumors and account for about 60% 
of all primary central nervous system (CNS) cancers (1). Around 23,880 new cases of primary CNS 
tumors are expected to be diagnosed in the United States in 2018 (2). Although rare—accounting for 
approximately 1.4% of all cancers (3)—they generally have a poor prognosis that leads to a dispro-
portionately high morbidity (patients often exhibit compromised basic and critical functions such 
as movement and speech) and high mortality (CNS tumors are 10th leading cause of death in the 
USA) (1). The 5-year survival rate for primary malignant brain and CNS tumors is the sixth lowest 
among all types of cancers after pancreatic, liver and intrahepatic bile duct, lung, esophageal, and 
stomach, making gliomas some of the most devastating types of cancers (2). Gliomas originate from 
astrocytes, oligodendrocytes, and ependymal cells and are consequently classified as astrocytomas, 
oligodendrogliomas, or ependymomas, respectively (4). According to the World Health Organization 
(WHO) criteria, gliomas are histologically graded into four grades (grade I–IV). Tumor grading 
correlates well with tumor morphology, biology, and prognosis.
FiGURe 1 | Oncoviruses, such as EBV, CMV, HH6, adenovirus, HSV 1/2, and HPV (top left) have been linked to CNS tumors like gliomas based on various 
molecular biology techniques (bottom left). Current literature implicates multiple molecular pathways facilitating the formation of both low-grade and high-grade-
gliomas. Signaling aberrations mainly involve EGFR amplification; metabolic alteration via IDH1; manipulation of cell cycle, DNA repair and apoptosis via tyrosine 
kinase signaling ERK/ATK, cyclins, E2F, and p53; epigenetic silencing of DNA repair genes like MGMT; and activation of telomerases via mutations of TERT gene. 
Alkylating agents such as temozolomide alkylate/methylate, the DNA on guanine residues inducing DNA damage thereby induce apoptosis. Abbreviations: EBV, 
Epstein–Barr virus; CMV, cytomegalovirus; HH6, human herpes virus 6; HSV 1/2, herpes simplex virus type 1 and 2; HPV, human papillomavirus; PCR, polymerase 
chain reaction; RNA-Seq, RNA sequencing; NGS, next-generation sequencing; IHC, immunohistochemistry; ELISA, enzyme-linked immunosorbent assay; IDH, 
isocitrate dehydrogenase; TERT, telomerase reverse transcriptase; MGMT, O-6-methylguanine-DNA methyltransferase; EGFR, epidermal growth factor receptor; 
MAPK, mitogen-activated protein kinase; PIK3, phosphatidylinositol 3-kinase; mTOR, mechanistic target of rapamycin; ERK, extracellular signal-regulated kinases.
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Glioblastoma multiforme, a fatal grade IV glioma, is the most 
common glial tumor (accounting for 50–60% of all gliomas) and 
has the worst prognosis with a median survival of 12–15 months 
and a 5-year survival rate of less than 5% in adults and 16% in 
children (5–8). The current standard-of-care includes surgical 
reduction of the tumor mass following craniotomy and then 
radiation and chemotherapy with temozolomide (9). GBM is 
morphologically characterized by increased cellularity, marked 
nuclear atypia, abundant mitotic activity of neoplastic cells fol-
lowed by the neoangiogenesis, and/or tumor necrosis.
Recent advances in molecular profiling of brain tumors has led 
to better disease stratification by allowing a more clear distinction 
between the low-grade and high-grade gliomas (GBM) (10). As 
a result, the 2016 WHO classification of glial tumors has inte-
grated the classical tumor morphology with genomic alterations 
derived from molecular profiling studies (11, 12). Most gliomas 
harbor molecular alterations disrupting key signaling pathways 
involved in regulation of cell growth (e.g., receptor tyrosine 
kinases, MAPK/ERK PIK3CA/AKT/PTEN signaling pathways), 
cell cycle/DNA repair/apoptosis (e.g., retinoblastoma/E2F/p53), 
metabolism [e.g., isocitrate dehydrogenase (IDH1)], chromatin, 
and telomere length (13). Among the most relevant genetic 
alterations affecting GBM are mutations of the IDH gene that may 
be linked to survival (14, 15). The enzyme catalyzes the oxida-
tive decarboxylation of isocitrate to α-ketoglutarate and reduces 
NAD(P)+ to NAD(P)H (16). IDH has two isoforms (IDH1 
and IDH2) of which mutations in IDH1 are the most common 
(Figure 1). IDH gene mutations are present in only 5% primary 
and approximately 80% of secondary GBMs (14).
Epidermal growth factor receptor (EGFR) is commonly over-
expressed in GBM, most frequently due to EGFR gene amplifica-
tion and/or the EGFR variant III deletion mutation (EGFRvIII). 
EGFR gene amplification is observed in approximately 50% of 
GBMs, whereas EGFRvIII (Figure  1), a constitutively active 
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truncated form of the EGFR protein that lacks the extracellular 
domain, occurs in 20–30% of cases (11, 17–19). Indeed, targeted 
inhibition of EGFR or the tumor-specific EGFRvIII holds thera-
peutic promise and several clinical trials with specific tyrosine 
kinases as well as monoclonal antibodies are ongoing (20, 21).
O6-methylguanine-DNA methyltransferase (MGMT) is an 
enzyme that is involved in DNA repair. MGMT promoter meth-
ylation is commonly detected in GBMs (~35–50%), particularly 
among the secondary GBMs (10, 12). Epigenetic silencing of the 
MGMT DNA-repair gene by promoter methylation compromises 
DNA repair and has been associated with longer survival in 
patients with glioblastoma who receive alkylating agents includ-
ing temozolomide (Figure 1) (22–24).
Telomerase reverse transcriptase (TERT) is an enzyme that is 
responsible for adding nucleotides to telomeres. Telomerases are 
usually inactive in the adult normal cells, but can be reactivated 
(e.g., by mutations) in various cancers to promote oncogenesis 
(11). TERT gene mutations in GBMs are activating (usually in 
the TERT promoter region) (11). TERT gene mutations are par-
ticularly common in primary GBMs (Figure 1) (11, 14). Several 
therapeutic strategies for the inhibition of telomerases have been 
attempted (25).
In addition, GBMs are frequently affected by the various 
copy number aberrations (CNA). These involve gains at chro-
mosomes 7 (EGFR/MET/CDK6), 12 (CDK4 and MDM2), and 4 
(PDGFRA), while deletions are commonly observed at chromo-
somes 9 (CDKN2A/B) and 10 (PTEN) (13). A subset of GBMs 
may also have genetic alterations of PIK3CA, PIK3R1, NF1, and 
RB1 genes (13, 19).
Along with improved understanding of the role of cells in 
the tumor microenvironment (e.g., reactive astrocytes, activated 
macrophage, and glioma stem cells), micro RNAs, and long non-
coding RNAs in glioma progression (26–28), the above genomic 
and molecular changes are thought to be of growing importance 
in the diagnosis, development, classification, and therapy of glio-
mas. However, what actually triggers these molecular changes 
and oncogenesis in brain tumors remains poorly understood.
Possible viral etiology of Gliomas  
and Scope of Review
Although little is known about the etiology of GBM or other 
gliomas, increased risk has been observed following exposure 
to ionizing radiation (8) or chemical agents or through genetic 
predisposition (e.g., germline TP53, NF1, and NF2 mutations) in 
a small proportion of the patients with GBM (e.g., Li–Fraumeni 
syndrome, neurofibromatosis type 1 and type 2) (8). More recently, 
increasing emphasis has been placed on a viral etiology of gliomas 
as they might serve as oncomodulators (29, 30). Oncomodula - 
tion refers to the ability of viral proteins and non-coding RNAs 
to promote oncogenic processes without direct oncotransforma-
tion, but through disturbances in various intracellular signaling 
pathways (30).
Viruses may contribute toward oncogenesis and tumor devel-
opment in humans by inducing immunosuppression, modify-
ing host cells through inducing oncoproteins, or altering the 
expression of host cell proteins at viral integration sites (29, 31). 
Pagano and colleagues have recently reviewed the most common 
cancer-causing viruses (31). Viruses such as human papillomavi-
rus (HPV) and human cytomegalovirus (CMV)—also known as 
human herpes virus-5 are strongly linked to the etiology and pro-
gression of cervical and colorectal cancers, respectively (32, 33). 
Several viruses have been linked to the etiology of brain tumors 
including CMV and other herpes viruses, such human herpes 
virus 6 (HHV-6 or roseolovirus), John Cunningham Virus (JCV; 
a polyomavirus); adenoviruses and Simian virus 40 (SV40), 
and others (30, 34). However, in the case of brain tumors, there 
is contradictory and/or controversial evidence linking many 
of these viruses, especially CMV—a ubiquitous herpes virus 
(32, 35). Because of its affinity for glial cells and its ability to 
reduce apoptosis, increase cell invasion, activate telomerase, and 
enhance angiogenesis in tumor cells (36, 37), several studies have 
investigated the role of CMV in glioma etiology. The first-ever 
study by Cobbs et al. in 2002 reported that CMV gene products 
and nucleic acids were present in all 27 glioma samples investi-
gated, without being detected in other brain tissue (38). Despite 
confirmatory reports from other research groups (39, 40), 
recent conflicting reports showing no association of CMV in 
brain tissues (35, 41) have cast doubt on the role of CMV in brain 
tumors.
While the majority of the literature concerning viruses in glio-
blastoma thus far had focused on CMV, more recently attention 
has shifted to another potential oncovirus, EBV, and its role in the 
etiology of gliomas (Figure 1). In this review article, we will focus 
on providing a comprehensive review of the literature pertaining 
to EBV in gliomas and discuss the possibilities of this virus being 
causative, simply associative, or even an experimental artifact has 
been suggested by some recent highly sensitive “state of the art” 
next-generation sequencing-based virome detection assays.
eBv and Tumorigenesis
Epstein–Barr virus, named after Michael Anthony Epstein and 
Yvonne Barr is also known as HHV-4, and was the first recognized 
human oncovirus (42). It belongs to the group of gamma-herpes 
viruses and is present in more than 90% of the human adult 
population who largely remain asymptomatic (43) with the main 
mode of transmission being via salivary and genital fluids (44). 
EBV, along with other herpes virus family members, is responsible 
for infections widely spread in the general population. Exposure 
mostly occurs in childhood or young adulthood followed by 
lifelong persistence of the virus. Thus, EBV has two distinct life 
cycles in humans: an acute lytic cycle, during which the produc-
tion of new virions occurs; and a latent form, in which the EBV 
remains “hidden” in the host. Although, EBV typically remains 
in memory B-cells, in a latent phase, it may also be detected in 
epithelial cells (oropharynx) as well as in certain subsets of T and 
NK cells (44).
Epstein–Barr virus is a DNA virus whose genome is approxi-
mately 172 kb in length (44). Binding of its surface protein gp350 
with CD21 receptor [also known as complement receptor 2 
(CR2)] followed by viral glycoprotein gp42 interaction with cel-
lular MHC class II molecules represents the major cellular fusion 
and entry mechanism into B-cells, whereas entry into epithelial 
cells is facilitated by viral protein BMRF-2 binding to cellular β1 
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integrins (44, 45). Subsequent to primary infection and replica-
tion within the lytic cycle, most of EBV genes are turned off as the 
virus switches to the latent phase (29).
During latency, EBV genome circular DNA resides in the cell 
nucleus as an episome and is copied by cellular DNA polymerase. 
In latency, only a portion of EBV’s genes including the six EBV 
nuclear oncoproteins (EBNA1, -2, -3A, -3B, -3C, and -LP) and 
the three latent membrane proteins (LMP1, -2A, and -2B), as well 
as several non-coding RNAs (EBERs and miRNAs) (46–49) are 
expressed in one of three patterns, known as latency programs 
(namely latency I, latency II, and latency III). Each latency pro-
gram, therefore, leads to the production of a limited, distinct set 
of viral proteins, and viral RNAs. As mentioned EBV can latently 
persist within B  cells and epithelial cells, but different latency 
programs are possible in the two types of cell (50, 51). In cases of 
EBV-associated cancers, there is differential expression of viral 
latency genes. However, emerging evidence suggests that of these, 
LMP1 is a major EBV-oncoprotein, as it provokes a multitude 
of effects enhancing cell growth, protecting cells from apoptosis, 
promoting cell motility and angiogenesis, and it is frequently 
expressed in EBV-linked human oral carcinomas (52–54).
Severe infections with EBV can cause infectious mononucleo-
sis (glandular fever), and its latent state can revert (i.e., reactivate 
virus) to yield multiple lymphoid and epithelial malignancies, 
including B-cell lymphomas (Burkitt’s lymphoma, Hodgkin’s 
lymphoma (HL), post-transplant lymphoproliferative disorder), 
various T-cell/NK lymphoproliferative disorders, undifferenti-
ated nasopharyngeal, and gastric carcinomas (55–57). Recent 
investigations including three from the Middle East, suggest that 
EBV is also present in around 40% of human breast malignancy 
where its occurrence is linked with more aggressive pheno- 
types (58–64).
Epstein–Barr virus can induce several molecular signaling 
changes in tumors such as those described in HL and undiffer-
entiated nasopharyngeal carcinoma. Approximately 50% of HLs 
are associated with EBV infection, particularly its lymphocyte-
depleted and mixed-cellularity variants. Reed–Sternberg (RS) 
giant cells represent characteristic B lymphocyte transformed 
neoplastic cells in HL, which are infected by EBV. Activation and 
survival of these cells are largely dependent on NF-ĸB upregula-
tion through the intimate interaction of CD40 receptor and 
LMP1 oncoprotein of EBV (65). In addition, several signaling 
pathways may also be upregulated by this interaction, including 
MAPK/ERK, PIK3CA/AKT, JAK/STAT, and Notch pathways 
(44). EBNA-1 is another important EBV product that is required 
for the replication and maintenance of EBV genome in cancer 
cells (44). Thus, in case of undifferentiated nasopharyngeal car-
cinoma, LMP1, LMP2, and EBNA1 products of EBV are actively 
involved in promotion of cell growth and anti-apoptotic effects in 
neoplastic cells (66), while LMPA2A is responsible for preventing 
the differentiation of the epithelial cells (46). All these EBV prod-
ucts are also involved in other processes (e.g., immune evasion, 
metastasis) that contribute a highly aggressive phenotype and 
poor clinical outcome of undifferentiated nasopharyngeal carci-
nomas (66). Of note, EBV presence has been well documented in 
several other cancers, including breast, prostate, oral, and salivary 
gland carcinomas (67–70).
eBv AND GLiOMAS
Although the role of EBV in B-cell lymphomas and nasopharyn-
geal carcinomas is well-defined, its role in gliomas is only recently 
being explored. EBV, whose main latent reservoir is thought to 
be B-cells in the bone marrow, is also known to be present in 
the brain. Although rare, EBV infections can be found in the 
CNS especially in immunocompromised patients as exempli-
fied by a case of EBV-induced encephalitis (71). Further, EBV 
is causally associated with a number of other CNS disorders 
[infectious mononucleosis, acute encephalitis, acute cerebellar 
ataxia, demyelinating disease, myelitis or meningitis, and some 
CNS neuropathies (72)]. The major cellular receptor for EBV, 
compliment receptor 2 (CR2) appears to be present on astrocytes 
(73) facilitates entry to infect astrocyte cell lines (74), and leads 
to increased proliferation. Importantly, primary CNS lymphomas 
(e.g., diffuse large B-cell lymphomas and lymphoid granuloma-
tosis) are frequently EBV-positive (75). Thus, the fact that EBV is 
also thought to be the causative agent for primary CNS lympho-
mas in immune-deficient patients has led to its investigations in 
other brain tumors including gliomas.
Literature Survey of eBv in Gliomas
In this section, we provide a detailed review of the key studies 
on EBV in gliomas (see Table  1). We searched the PubMed/
MEDLINE databases using the following key words, such as 
glioma(s), glioblastoma multiforme, brain tumors/cancers, EBV, 
and neurotropic viruses. Our literature search was not time 
limited.
Several, but not all, of the studies conducted across different 
geographical locations, such as North America, South America, 
Europe, and Japan, have shown a positive association of EBV 
in patients with gliomas (Table 1). Recently, Stojnik et  al. (34) 
studied the presence of EBV, along with HSV-2, HHV-6, and 
one human enterovirus (hEV) in high-grade gliomas in 45 adult 
patients (12 with grade III and 33 with grade IV) at the University 
Clinical Centre in Maribor, Slovenia. Glioma tissue samples 
were obtained either from tumor biopsies (19/45) or following 
surgical tumor reduction (26/45) from patients with a median 
age of 60 years (ranging from 22 to 86 years). Tissue was either 
used within 24  h for assaying of viral genes by rt-PCR (in the 
case of EBV, a 166 bp fragment of the ebna gene was amplified). 
Serum analyses of C-reactive protein (CRP) was measured for all 
patients (24 whom were females) and 30/45 patient samples were 
also analyzed for specific antibodies for each of the viruses by 
enzyme immunoassays and complement fixation. PCR studies of 
gliomas revealed only 3/45 patients were positive for EBV ebna 
gene: a 66-year-old male with GBM located in the left temporal 
and parietal lobes; a 68-year-old female with GBM located in the 
right temporal and parietal lobes; and a 77-year-old male with 
GBM located in the right temporal, parietal, and occipital lobes. 
Common features were that all samples were attained following 
craniotomy and surgical tumor reduction. Importantly, all three 
EBV+ patients had grade IV gliomas (GBM) and no virus was 
detected in any of the 12 grade III gliomas, implying this virus 
is preferentially associated with most aggressive CNS tumors. 
However, none of the patients were found to be seropositive for 
TABLe 1 | Selected examples of studies investigating Epstein–Barr virus (EBV) in gliomas.
Reference Glioma type Sample size/tissue sampled Methodology Main findings
Strojnik et al. (34) High-grade 45 adult patients, tumor biopsy ebna RT-polymerase chain reaction (PCR) 3/45 (6.7%) positive
Wrensch et al. (76) High-grade 57 adult patients, serum  
analysis
Enzyme-linked immunosorbent assay (ELISA) for 
IgG in sera
86% positive
Poltermann et al. (77) High-grade 35 patients, serum analysis ELISA for IgG in sera 90% positive
Zavala-Vega et al. (78) High-grade 21 patients, tissue biopsy Detected latent membrane proteins (LMP-1) by 
immunohistochemistry and EBER expression by 
in situ hybridization, RT-PCR
6/21 (28.6%) positive
Fonseca et al. (79) Low-grade and 
high-grade
75 patients, tissue biopsy EBV using PCR with confirmation using direct 
sequencing
6/11 (55%) low-grade positive
3/22 (13.6%) high-grade positive
Cheng-Te Major Lin et al. (41) High-grade 19 patients, formalin-fixed  
glioma tissue
EBV lmp1 DNA with multiplex droplet digital PCR 4/19 (21%) positive
Neves et al. (80) Pilocytic 
astrocytoma
35 children, tissue biopsy RT-PCR, LMP1 by immunohistochemistry 9/35 (26%) positive by PCR, but 
none by immunohistochemistry
Cimino et al. (81) High-grade 21 patients, tissue biopsy Next-generation sequencing/PCR/in situ 
hybridization
5/21 (24%) positive, but  
none by in situ hybridization
Strong et al. (35) High-grade 170 patients, tissue biopsy Next-generation sequencing/RT-PCR None positive
Cosset et al. (82) High-grade 20 patients, tissue biopsy/ 
serum analysis
PCR None positive
Khoury et al. (83) Low- and 
high-grade
215 patients/tissue biopsy RNA-Seq database analyses None positive
Hashida et al. (84) High-grade 39 patients/tissue biopsy PCR analyses of LMP1 gene None positive
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EBV antibodies (34). This was in contrast to an earlier report by 
Wrensch et al. (76), who used serological IgG antibody binding 
using ELISA assays to demonstrate that about 90% of their GBM 
patients, from the USA, San Francisco Bay Area Adult Glioma 
Study from 1991 to 1995, were seropositive for EBV (76). Another 
study conducted by Poltermann et al. (77) showed the presence 
of IgG antibodies to EBV in serum of 89% (64/72) of patients 
with glial tumors (n = 35), meningiomas (n = 31), and acoustic 
schwanommas (n =  6) though this was not considered signifi-
cantly different to antibody levels in the general population (77).
Strojnik et al. (34) also found HHV-6 in 2/45, HSV2 in 1/45, 
and hEV in 1/45 glioma tissue samples tested. All positive tests 
were in grade IV gliomas but of varying origin. However, viral 
copy numbers for all viruses, including EBV, detected in glioma 
tissue samples were generally very low (mostly below 2 copies 
per 5 µL DNA with only the 66-year-old male with EBV having 
a copy number of 27 copies per 5 µL DNA). Again, none of the 
patients’ positive for HHV-6 or HSV2 in glioma tissues devel-
oped antibodies in serum samples though five positive results 
for HSV2 antibodies were noted even in the absence of virus in 
the tumor samples. Furthermore, the presence of adenoviruses, 
HSV-1, CMV, and VZV was not confirmed in any of the 45 tissue 
samples studied (34).
Another recent study by Zavala-Vega et  al. (78) reported 
on presence of EBV, along with CMV and HSV1/2 in Mexican 
patients with GBM. They performed a retrospective study using 
brain tissue from 21 adults aged on average 52  years (range 
23–83 years). To indicate EBV infection, they detected LMP-1 by 
immunohistochemistry and EBER expression by in situ hybridi-
zation in 6/21 (28.6%) of patients. Mixed infections of EBV and 
HSV-1/2 were noted in 4/21 patients (19%), whereas EBV and 
CMV in 5/21 (23.8%) patient samples. A particular limitation 
of this study was that IgG and IgM antibody levels could not 
be determined in patients with viral infections as this was a 
retrospective study based on paraffin-embedded tissue samples 
only. However, the value of measuring antibody titers may not 
correlate with disease as antibodies produced in the case of the 
related CMV during early stages of infections have a protective 
effect, thereby preventing viral reactivation and subsequent 
development of glioblastoma (85).
A study by Fonesca et  al. (79) aimed to screen 75 primary 
glioma biopsy specimens from a cancer centre in Rio de Janeiro, 
Brazil, for the presence of EBV using PCR with confirmation 
using direct sequencing. To detect EBV in tumor samples, a 
288  bp fragment of EBV bam region was amplified and later 
sequenced to confirm viral DNA in GeneBank data sets. Using 
this strategy in fresh frozen tissue samples, 11/75 gliomas (14.7%) 
were positive for EBV with the majority being low-grade gliomas 
(6/11), followed by 2/11 for grade III, oligoastrocytoma (1/11), 
ependymoma (1/11), and only 1/11 being grade IV (GBM). 
These results are in contrast to the study from Slovenia where 
only high-grade gliomas were positive for EBV (34). In addition, 
Fonesca et al. (79) also found EBV in one oligoastrocytoma and 
one ependymoma, but none at all in other CNS tumors including 
two non-HL—a tumor type in which EBV association has been 
reported previously (75). The amplified EBV gene sequences 
obtained from gliomas were well matched with published EBV 
genome sequences with an identicalness rate of 95.5% implying 
that EBV virus was indeed present in these samples.
Cheng-Te Major Lin et al. (41) used multiplex droplet digital 
PCR (ddPCR)—a highly precise diagnostic tool that enables 
the absolute quantification of target DNA in a high throughput 
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setting—to show positivity of EBV lmp1 DNA in 4/19 (21.1%) 
of formalin-fixed paraffin-embedded (FFPE) GBM samples and 
not in any controls. Samples were obtained from the George 
Washington University Hospital and the National Institutes of 
Health, USA. Interestingly, two GBM tumor specimens were 
positive for both HHV-6B and EBV indicating that the possibility 
of multiple viral infections being associated with GBMs.
Pilocytic astrocytoma of the cerebellum is one of the most 
common pediatric brain tumors. In FFPE tumor samples analyzed 
by two different PCR methodologies and immunohistochemistry, 
EBV was detected by PCR in about 30% of these tumors (9/35) 
from patients with an average age of 15.5 years; however, none 
of the samples were positive for EBV by immunohistochemistry 
(anti-LMP1 antibody) (80). Most of the astrocytoma (33/35) was 
of low-grade malignancy. This study suggested that EBV was 
the most frequent herpes virus found in pilocytic astrocytoma 
though at levels apparently too low to be considered responsible 
for tumor induction (80).
Because polymerase chain reaction (PCR) analyses and viral-
specific immunohistochemical assays are biased in that only 
selected or targeted genes or proteins of viruses are investigated in 
tumors, more state-of-the art methods with high sensitivity that 
may avoid these bias are being used to detect infectious agents in 
tumors. A less biased approach would be to fully sequence brain 
tumors and search for any EBV virome nucleic acid sequences 
present. One such methodology that allows this rather unbiased 
approach is next-generation sequencing (NGS)—a non-Sanger-
based high-throughput DNA sequencing technology. There are a 
number of different NGS platforms, a detailed discussion of which 
is beyond the scope of this article, but the reader is referred to some 
recent review (86–88). Nonetheless, in all NGS platforms sequenc-
ing of millions of small fragments of DNA in parallel is followed 
by bioinformatics analyses to piece together these fragments and 
mapping the individual reads to the reference genome. NGS can be 
used to sequence entire genomes or constrained to specific genes 
or regions of interest. Recently, NGS studies have been used to 
study the presence of EBV sequences in gliomas (71, 81).
A NGS study by Cimino et al. (81) examined viral sequences 
in 21 high-grade gliomas (mostly glioblastomas) at the University 
of Washington, St Louis, MO, USA. Unmapped sequencing reads, 
obtained from FFPE samples, identified EBV in 5/21 (24%) of 
high-grade gliomas (all GBM). They also found one case of 
Roseolovirus, but no CMV in any of their glioma tissues. However, 
further examination of the four of EBV-sequence-positive tumors 
for virus by in  situ-hybridization failed to detect EBV-encoded 
RNA implying that EBV in malignant high-grade gliomas might 
be transcriptionally inactive and more characteristic of a dormant 
state that could also be present in the general population (81). 
However, since the authors examined only one non-coding 
EBER RNA, the possibility that other EBV RNAs may be pro-
duced still remains unexplored.
Contrary to the findings of Cimino et al. (81), a more recent 
and very comprehensive NGS study by Strong et al. (35) suggested 
that no major viruses were associated with high-grade gliomas. 
These authors undertook a large-scale virome assessment in pub-
lically available The Cancer Genome Atlas (TCGA) sequencing 
data sets for 157 primary glioblastomas (GBM) and 13 recurrent 
GBM as well as whole genome sequencing (WGS) data sets for 51 
primary GBM, and 10 recurrent GBM. Finally, they also analyzed 
fresh frozen tissue from three primary GBM samples (one from 
a patient at the Louisiana Cancer Research Consortium and two 
samples from the commercial supplier BioServe, USA). In this 
comprehensive and detailed study, the authors aimed to address 
many of the major experimental concerns in detecting viruses 
in tumor tissues (35). For instance, to account for heterogene-
ity within GBM tumor mass that might give rise to differential 
transcriptome profiles (89), they used data sets from 92 MRI-
localized biopsies from either the core or margins of multiple 
GBM patients; and to account for the possibility that viruses may 
lay hidden within cancer stem cells, they also analyzed RNA-seq 
data sets from a cohort of short-term glioma stem cell cultures 
freshly isolated from nine patients with primary GBM. Despite 
these precautionary measures, as well as running NGS experi-
ments at low viral read thresholds (that could have been associ-
ated with increased risk of low-level contamination), no major 
virus associations could be identified. However, in their attempt 
to account for the possibility that viruses infecting brain tissue 
become transcriptionally dormant and thus avoid detection in 
RNA-seq data sets, they also looked at WGS data sets for virome 
assessment. Analyses of the virus at the DNA level did show low 
level presence of EBV DNA in samples (at viral reads below 40) 
from 9 primary GBM and 6 matched blood samples as well as 3 
recurrent GBM each from the TCGA and WGS data sets with 
only one having a moderate EBV viral read of 1,454. However, the 
presence of EBV DNA in the case of the three recurrent GBM from 
WGS data could not be validated by the corresponding RNA-seq 
data. As true, EBV association would normally lead to much 
higher viral reads (>10 for RNA-seq and >1,000s for DNA-seq) 
and given the presence of EBV in blood and tumor specimens was 
roughly equivalent, the authors concluded that the detected EBV 
likely originated from infiltrating EBV-infected B-cells and/or 
from possible library or sequencing sample cross-contamination.
Similarly, they also dismissed low-level viral reads of several 
other viruses in gliomas, as likely artifacts or non-pathological 
incidental infections. For example, they noted that all of the spo-
radic low-level CMV reads were found to map to the immediate 
early promoter intimating that they likely originated from labora-
tory expression vector contamination. In addition, human herpes 
virus 6 and 7 aligned viral reads were likely false-positives due to 
their homology with human telomeric-like repeats (35). These 
data argue against associations between most known viruses and 
GBM or meningiomas, but interestingly, the authors highlighted 
that the most robust virus findings were the detection of HPV and 
hepatitis B in the occasional low-grade gliomas. Thus, although 
these findings cast doubt on EBV association in gliomas they 
rather, open the door for the further in-depth studies on the pos-
sible association of HPV and hepatitis B, two viruses that have 
received little attention in CNS tumors including gliomas.
Several other studies have reported on the complete absence 
of EBV in gliomas. Cosset et al. (82) studied 20 GBM biopsies 
including the corresponding patient serum, where available, by 
standard clinical diagnostic methods (semi-qPCR) for the pres-
ence of the following common neurotropic viruses: CMV, EBV, 
HSV, HHV6, MeV, PeV, JC virus, EV, and VZV. Although some 
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biopsies were associated with a type I IFN-response, none of the 
above-mentioned viruses were detected in any sample of GBM 
or of three other low-grade gliomas, one oligodendroglioma, two 
meningiomas, one ependymoma, and one oligoastrocytoma (82). 
Similarly, Khoury et al. (83) reported no EBV or any other virus 
after screening of TCGA malignant tumors including low- and 
high-grade gliomas on which RNA-Seq data were available. They 
showed no evidence of transcribed viral elements in any of the 
low-grade gliomas and glioblastoma multiforme. Further, a study 
by Hashida et al. (84) in Japanese subjects with GBMs failed to 
detect EBV in tumors using real-time PCR analyses of LMP1 
gene. However, these authors did show the presence of high risk 
HPV16 and HPV18 in 21% (8/39) of the GBMs studied—results 
that are consistent with the findings of Vidone et al. (90) in Italian 
glioma patients and reaffirmed in the NGS study of Strong et al. 
(35) discussed above (see also Table 1).
PeRSPeCTiveS AND CONCLUDiNG 
ReMARKS
It is clear from the studies examining EBV in gliomas conducted 
thus far that, as is the case with other viruses like CMV, there 
are discordant results on viral association in these malignancies. 
Reasons for these discordant findings may lie within population/
geographic differences, individual genetic variability, inherent 
heterogeneity of gliomas, variations in samples including ana-
tomical location from which tumor specimen was removed, dif-
ferences in the actual viral genes probed, as well as sensitivity and 
precision of the methodologies used. In addition, differences in 
processing or preparation of samples (such as section thickness, 
fixation conditions, and antibody dilution) and difficulties with 
paraffin-embedded tumor samples may have caused the observed 
discrepancies (32, 91). Are these variables really the explanation? 
Probably, in part but surely, an ideally robust association of EBV 
in gliomas would have resulted in sufficiently high viral levels to 
the extent that the effects of many of the above variables would 
be minimal or at least mitigated to some extent. However, a few 
studies have shown no virus and most have shown only low 
levels of the EBV either in the glioma tissue or as antibodies in 
serum including the recent elegant and comprehensive study by 
Strong et al. (35) that aimed to account for many of the concerns 
mentioned above.
Serological studies measuring EBV antibodies in glioma 
patients were also discordant. Given the fact that 90% of the 
population is carriers of EBV in its latent state, why are we not, 
therefore, detecting a similar proportion of seropositive tumor 
patients as the general population in all studies? For example, in 
one study, the risk of glioma patients being seropositive for EBV 
was less than the control population implying that the tumor may 
actually modulate EBV infections. The presence of lower levels of 
EBV in tumor than in control samples could also be explained if 
the virus was lost during tumor progression. Such a “hit and run” 
model has been proposed in HPVs (28, 92). There is also evidence 
indicating the presence of EBV antibodies early on may actually 
be protective in tumors (93). In any case, the high seroprevalence 
of EBV in controls makes it difficult to make a firm association 
based on the serum antibody data presented for EBV in gliomas.
Thus, can we really exclude a clinical role of EBV in gliomas 
based on these findings or could the relatively low levels of EBV, 
as generally reported in gliomas, still lead to gliomagenesis and/
or oncomodulation? A recent report by Shumilov et al. (94) sug-
gests that EBV might exert some of its oncogenic effects, such as 
inducing centrosome amplification and chromosomal instability, 
without having to establish a chronic infection, thereby confer-
ring a risk for development of tumors that do not necessarily 
carry the viral genome (94).
Lytic replication, the process by which viral progeny is pro-
duced, is a strong risk factor for EBV-associated tumors (31). 
This process activates cellular cancer-associated changes such 
as chromosomal instability, but lytic replication also leads to 
cell death rendering the link between replicating cells and onco-
genesis not so obvious. Shumilov et al. (94) presented the data 
that removed this conceptual difficulty by showing that the EBV 
virions themselves conferred the risk induced by lytic replication 
to non-replicating cells, i.e., the effects of EBV virions extended to 
EBV-negative cells. Thus, their paradigm-changing study implies 
that EBV could be a risk factor for the development of gliomas 
without being present in the tumor. If others confirm these find-
ings, then this would fundamentally change our view of the role 
played by EBV in tumors and offer a more rational explanation 
for the near absence of EBV in gliomas reported in several of the 
studies reviewed herein.
Since direct viral association studies have generally been 
discordant, another approach to establish viral association with 
tumors has been to study the role of antiviral therapies on disease 
(91). A recent report has suggested that glioma patients at the 
Karolinska University Hospital receiving 6  months of antiviral 
therapy as an add-on to standard radiation and temozolamide 
therapy exhibited marked increases in survival rates (95), though 
the study design and mathematics used have been questioned 
(23, 95). Some other studies, but not all, have also shown improved 
outcomes in cancer patients on antiviral therapy (32, 96). How-
ever, while the rates of many AIDS-associated malignancies 
have been declining with the use of highly active anti-retroviral 
therapy, the rates of EBV-positive Burkitt’s and HL in this popula-
tion have not declined (97, 98). These data may imply that the 
oncogenic effects of EBV—at least in B-cell lymphomas—are not 
affected by antiretroviral drugs. It should, however, be noted that 
while viral therapy may improve clinical outcome in some cases, 
it does not necessarily imply a viral cause as survival benefit might 
be explained by secondary or “off-target” effects of the therapy 
alone unrelated to viral infection.
In contrast, there is also evidence to suggest that prior expo-
sure to stress and/or immunodeficient status induced by therapies 
may actually predispose patients to EBV-induced oncogenesis. 
For example, Zakaria et al. (99) described a patient who within 
2  months of undergoing radio-chemotherapy for glioblastoma 
developed an EBV-positive primary diffuse large B-cell CNS 
lymphoma (99). These findings suggest that probably the immu-
nosuppression and/or stress induced by the treatments for GBM, 
or even co-morbidities, can lead to EBV reactivation.
A corollary of this is the idea that stress resulting from 
co-infections may also be important in viral reactivation and 
oncogenesis. Although the low levels of EBV infections reported 
8
Akhtar et al. EBV in Gliomas
Frontiers in Oncology | www.frontiersin.org April 2018 | Volume 8 | Article 123
in gliomas, by themselves may not be sufficient, they likely require 
additional stress-causing risk factors, such as the co-presence of 
other oncoviruses, to influence oncogenesis or oncomodulation. 
Thus, latent EBV viruses may be reactivated when cells experi-
ence co-infection with, for example, CMV or HSV1/2, as has been 
reported in some glioma studies (78).
In this regard, a preventative vaccine against EBV and/or co-
infecting agent may be useful. Vaccines against specific viruses 
may, therefore, offer a more targeted approach for association 
studies and clinical therapy [for review see Cohen (100)]. For 
example, an EBV vaccine has been tested (in a phase I clinical 
trial) on Chinese nasopharyngeal carcinoma patients to deter-
mine the safe and immunogenic dose (101). In that study, it was 
concluded that the vaccine is both safe and immunogenic, thus 
paving the way for further clinical testing of the EBV vaccine 
that may be of clinical benefit in EBV-positive tumors including 
glioma patients. The first prophylactic EBV vaccine based on 
virus-like particles (VLPs) that mimic the structure of the EBV 
virus, but lack its genome has also been reported to be effective 
in preclinical models (102) and may represent a safer alternative.
Finally, could it be that by looking for EBV and other herpes 
viruses like CMV, in gliomas we might have been focusing on the 
wrong viruses? Recent NGS sequencing data seems to suggest that 
most of the viruses especially CMV are completely absent from 
gliomas and many of the positive associations reported are likely 
artifactual as they may be rationally explained otherwise [e.g., 
high homology of detected viral sequences to host as in the case of 
chromosomal telomere repeats (35)]. The reported low level pres-
ence of EBV does not completely rule it out from being associated 
with oncogenesis or oncomodulation in gliomas [indeed, it may 
not even need to be present to exert its effects as suggested by the 
study of Shumilov et al. (94)], but recent reports suggest that HPV 
infection might be more robustly associated with some gliomas. 
Thus, additionally more detailed and comprehensive studies are 
needed to fully implicate EBV and/or other viruses such as HPV 
in having a direct association in gliomagenesis and oncomodula-
tion. Understanding the role of EBV and other oncoviruses in the 
etiology of gliomas, that generally have a poor prognosis, would 
likely open up new avenues for the treatment and management of 
these, often fatal, CNS tumors.
AUTHOR CONTRiBUTiONS
SA and A-EM conceived the review. SA and SV searched the lit-
erature. SA, SV, FC, and A-EM critically appraised the literature, 
wrote and approved final version of the manuscript.
ReFeReNCeS
1. McFaline-Figueroa JR, Lee EQ. Brain tumors. Am J Med (2018). doi:10.1016/j.
amjmed.2017.12.039 
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 
(2018) 68:7–30. doi:10.3322/caac.21442 
3. Gladson CL, Prayson RA, Liu WM. The pathobiology of glioma tumors. Annu 
Rev Pathol (2010) 5:33–50. doi:10.1146/annurev-pathol-121808-102109 
4. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med (2008) 
359:492–507. doi:10.1056/NEJMra0708126 
5. Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, et al. 
Maintenance therapy with tumor-treating fields plus temozolomide vs temo-
zolomide alone for glioblastoma: a randomized clinical trial. JAMA (2015) 
314:2535–43. doi:10.1001/jama.2015.16669 
6. Cohen KJ, Pollack IF, Zhou T, Buxton A, Holmes EJ, Burger PC, et  al. 
Temozolomide in the treatment of high-grade gliomas in children: a report 
from the Children’s Oncology Group. Neuro Oncol (2011) 13:317–23. 
doi:10.1093/neuonc/noq191 
7. Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al. The 
epidemiology of glioma in adults: a “state of the science” review. Neuro Oncol 
(2014) 16:896–913. doi:10.1093/neuonc/nou087 
8. Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee ShU. Glioblastoma 
multiforme: a review of its epidemiology and pathogenesis through clini-
cal presentation and treatment. Asian Pac J Cancer Prev (2017) 18:3–9. 
doi:10.22034/APJCP.2017.18.1.3
9. Bovenberg MS, Degeling MH, Tannous BA. Cell-based immunotherapy 
against gliomas: from bench to bedside. Mol Ther (2013) 21:1297–305. 
doi:10.1038/mt.2013.80 
10. Diamandis P, Aldape KD. Insights from molecular profiling of adult glioma. 
J Clin Oncol (2017) 35:2386–93. doi:10.1200/JCO.2017.73.9516 
11. Bush NA, Butowski N. The effect of molecular diagnostics on the treatment of 
glioma. Curr Oncol Rep (2017) 19:26. doi:10.1007/s11912-017-0585-6 
12. Olar A, Aldape KD. Using the molecular classification of glioblastoma to 
inform personalized treatment. J Pathol (2014) 232:165–77. doi:10.1002/
path.4282 
13. Touat M, Idbaih A, Sanson M, Ligon KL. Glioblastoma targeted therapy: 
updated approaches from recent biological insights. Ann Oncol (2017) 
28:1457–72. doi:10.1093/annonc/mdx106 
14. Lieberman F. Glioblastoma update: molecular biology, diagnosis, treatment, 
response assessment, and translational clinical trials. F1000Res (2017) 
6:1892. doi:10.12688/f1000research.11493.1 
15. Waitkus MS, Diplas BH, Yan H. Isocitrate dehydrogenase mutations in 
gliomas. Neuro Oncol (2016) 18:16–26. doi:10.1093/neuonc/nov136 
16. Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: 
alterations at a crossroads of cellular metabolism. J Natl Cancer Inst (2010) 
102:932–41. doi:10.1093/jnci/djq187 
17. Aldape K, Zadeh G, Mansouri S, Reifenberger G, Von Deimling A. 
Glioblastoma: pathology, molecular mechanisms and markers. Acta 
Neuropathol (2015) 129:829–48. doi:10.1007/s00401-015-1432-1 
18. Mishra R, Hanker AB, Garrett JT. Genomic alterations of ERBB receptors in 
cancer: clinical implications. Oncotarget (2017) 8:114371–92. doi:10.18632/
oncotarget.22825 
19. Brennan CW, Verhaak RG, Mckenna A, Campos B, Noushmehr H, Salama SR, 
et al. The somatic genomic landscape of glioblastoma. Cell (2013) 155:462–77. 
doi:10.1016/j.cell.2013.09.034 
20. Xu H, Zong H, Ma C, Ming X, Shang M, Li K, et  al. Epidermal growth 
factor receptor in glioblastoma. Oncol Lett (2017) 14:512–6. doi:10.3892/
ol.2017.6221 
21. Padfield E, Ellis HP, Kurian KM. Current therapeutic advances targeting 
EGFR and EGFRvIII in glioblastoma. Front Oncol (2015) 5:5. doi:10.3389/
fonc.2015.00005 
22. Dullea A, Marignol L. MGMT testing allows for personalised therapy in 
the temozolomide era. Tumour Biol (2016) 37:87–96. doi:10.1007/s13277- 
015-4240-2 
23. Wick W, Weller M, Van den Bent M, Sanson M, Weiler M, Von Deimling A, 
et al. MGMT testing – the challenges for biomarker-based glioma treatment. 
Nat Rev Neurol (2014) 10:372–85. doi:10.1038/nrneurol.2014.100 
24. Hegi ME, Diserens AC, Gorlia T, Hamou MF, De Tribolet N, Weller M, et al. 
MGMT gene silencing and benefit from temozolomide in glioblastoma. 
N Engl J Med (2005) 352:997–1003. doi:10.1056/NEJMoa043331 
25. Yaswen P, Mackenzie KL, Keith WN, Hentosh P, Rodier F, Zhu J, et  al. 
Therapeutic targeting of replicative immortality. Semin Cancer Biol (2015) 
35(Suppl):S104–28. doi:10.1016/j.semcancer.2015.03.007 
26. Kamran N, Alghamri MS, Nunez FJ, Shah D, Asad AS, Candolfi M, 
et  al. Current state and future prospects of immunotherapy for glioma. 
Immunotherapy (2018) 10:317–39. doi:10.2217/imt-2017-0122 
9
Akhtar et al. EBV in Gliomas
Frontiers in Oncology | www.frontiersin.org April 2018 | Volume 8 | Article 123
27. Yin J, Valin KL, Dixon ML, Leavenworth JW. The role of microglia and 
macrophages in CNS homeostasis, autoimmunity, and cancer. J Immunol 
Res (2017) 2017:5150678. doi:10.1155/2017/5150678 
28. Huang SW, Ali ND, Zhong L, Shi J. MicroRNAs as biomarkers for human 
glioblastoma: progress and potential. Acta Pharmacol Sin (2018). doi:10.1038/
aps.2017.173 
29. Elgui de Oliveira D, Muller-Coan BG, Pagano JS. Viral carcinogenesis 
beyond malignant transformation: EBV in the progression of human cancers. 
Trends Microbiol (2016) 24:649–64. doi:10.1016/j.tim.2016.03.008 
30. Kofman A, Marcinkiewicz L, Dupart E, Lyshchev A, Martynov B, Ryndin A, 
et  al. The roles of viruses in brain tumor initiation and oncomodulation. 
J Neurooncol (2011) 105:451–66. doi:10.1007/s11060-011-0658-6 
31. White MK, Pagano JS, Khalili K. Viruses and human cancers: a long road 
of discovery of molecular paradigms. Clin Microbiol Rev (2014) 27:463–81. 
doi:10.1128/CMR.00124-13 
32. Alibek K, Kakpenova A, Baiken Y. Role of infectious agents in the carcino-
genesis of brain and head and neck cancers. Infect Agent Cancer (2013) 8:7. 
doi:10.1186/1750-9378-8-7 
33. Michaelis M, Doerr HW, Cinatl J. The story of human cytomegalovirus 
and cancer: increasing evidence and open questions. Neoplasia (2009) 
11:1–9. doi:10.1593/neo.81178 
34. Strojnik T, Duh D, Lah TT. Prevalence of neurotropic viruses in malignant 
glioma and their onco-modulatory potential. In  Vivo (2017) 31:221–9. 
doi:10.21873/invivo.11049 
35. Strong MJ, Blanchard ET, Lin Z, Morris CA, Baddoo M, Taylor CM, et al. 
A comprehensive next generation sequencing-based virome assessment in 
brain tissue suggests no major virus-tumor association. Acta Neuropathol 
Commun (2016) 4:71. doi:10.1186/s40478-016-0338-z 
36. Straat K, Liu C, Rahbar A, Zhu Q, Liu L, Wolmer-Solberg N, et al. Activation of 
telomerase by human cytomegalovirus. J Natl Cancer Inst (2009) 101:488–97. 
doi:10.1093/jnci/djp031 
37. Soderberg-Naucler C. HCMV microinfections in inflammatory diseases 
and cancer. J Clin Virol (2008) 41:218–23. doi:10.1016/j.jcv.2007.11.009 
38. Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, et al. 
Human cytomegalovirus infection and expression in human malignant 
glioma. Cancer Res (2002) 62:3347–50. 
39. Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, Mclendon RE, 
et  al. Sensitive detection of human cytomegalovirus in tumors and peri - 
pheral blood of patients diagnosed with glioblastoma. Neuro Oncol (2008) 
10:10–8. doi:10.1215/15228517-2007-035 
40. Scheurer ME, Bondy ML, Aldape KD, Albrecht T, El-Zein R. Detection 
of human cytomegalovirus in different histological types of gliomas. Acta 
Neuropathol (2008) 116:79–86. doi:10.1007/s00401-008-0359-1 
41. Lin CT, Leibovitch EC, Almira-Suarez MI, Jacobson S. Human herpesvirus 
multiplex ddPCR detection in brain tissue from low- and high-grade astro-
cytoma cases and controls. Infect Agent Cancer (2016) 11:32. doi:10.1186/
s13027-016-0081-x 
42. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts 
from Burkitt’s lymphoma. Lancet (1964) 1:702–3. doi:10.1016/S0140- 
6736(64)91524-7 
43. Niedobitek G, Meru N, Delecluse HJ. Epstein-Barr virus infection and 
human malignancies. Int J Exp Pathol (2001) 82:149–70. doi:10.1111/ 
j.1365-2613.2001.iep190.x 
44. Mui UN, Haley CT, Tyring SK. Viral oncology: molecular biology and 
pathogenesis. J Clin Med (2017) 6(12). doi:10.3390/jcm6120111 
45. Odumade OA, Hogquist KA, Balfour HH Jr. Progress and problems in 
understanding and managing primary Epstein-Barr virus infections. Clin 
Microbiol Rev (2011) 24:193–209. doi:10.1128/CMR.00044-10 
46. Guidry JT, Scott RS. The interaction between human papillomavirus and 
other viruses. Virus Res (2017) 231:139–47. doi:10.1016/j.virusres.2016. 
11.002 
47. Middeldorp JM, Brink AA, Van Den Brule AJ, Meijer CJ. Pathogenic roles 
for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative 
disorders. Crit Rev Oncol Hematol (2003) 45:1–36. doi:10.1016/S1040- 
8428(02)00078-1 
48. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 
(2004) 4:757–68. doi:10.1038/nrc1452 
49. Murata T, Tsurumi T. Switching of EBV cycles between latent and lytic states. 
Rev Med Virol (2014) 24:142–53. doi:10.1002/rmv.1780 
50. Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res 
(2004) 10:803–21. doi:10.1158/1078-0432.CCR-0670-3 
51. Munz C, Moormann A. Immune escape by Epstein-Barr virus asso-
ciated malignancies. Semin Cancer Biol (2008) 18:381–7. doi:10.1016/ 
j.semcancer.2008.10.002 
52. Kaye KM, Izumi KM, Kieff E. Epstein-Barr virus latent membrane protein 1 
is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci U S A 
(1993) 90:9150–4. doi:10.1073/pnas.90.19.9150 
53. Morris MA, Dawson CW, Young LS. Role of the Epstein-Barr virus-encoded 
latent membrane protein-1, LMP1, in the pathogenesis of nasopharyngeal 
carcinoma. Future Oncol (2009) 5:811–25. doi:10.2217/fon.09.53 
54. Dawson CW, Port RJ, Young LS. The role of the EBV-encoded latent 
membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyn-
geal carcinoma (NPC). Semin Cancer Biol (2012) 22:144–53. doi:10.1016/ 
j.semcancer.2012.01.004 
55. de Lima MAP, Neto PJN, Lima LPM, Goncalves Junior J, Teixeira Junior AG, 
Teodoro IPP, et al. Association between Epstein-Barr virus (EBV) and cervical 
carcinoma: a meta-analysis. Gynecol Oncol (2018) 148:317–28. doi:10.1016/ 
j.ygyno.2017.10.005 
56. Vedham V, Verma M, Mahabir S. Early-life exposures to infectious agents 
and later cancer development. Cancer Med (2015) 4:1908–22. doi:10.1002/
cam4.538 
57. Vockerodt M, Yap LF, Shannon-Lowe C, Curley H, Wei W, Vrzalikova K, et al. 
The Epstein-Barr virus and the pathogenesis of lymphoma. J Pathol (2015) 
235:312–22. doi:10.1002/path.4459 
58. Kalkan A, Ozdarendeli A, Bulut Y, Yekeler H, Cobanoglu B, Doymaz MZ. 
Investigation of Epstein-Barr virus DNA in formalin-fixed and paraffin- 
embedded breast cancer tissues. Med Princ Pract (2005) 14:268–71. 
doi:10.1159/000085748 
59. Fawzy S, Sallam M, Awad NM. Detection of Epstein-Barr virus in breast car-
cinoma in Egyptian women. Clin Biochem (2008) 41:486–92. doi:10.1016/j.
clinbiochem.2007.12.017 
60. Lorenzetti MA, De Matteo E, Gass H, Martinez Vazquez P, Lara J, Gonzalez P, 
et  al. Characterization of Epstein Barr virus latency pattern in Argentine 
breast carcinoma. PLoS One (2010) 5:e13603. doi:10.1371/journal.pone. 
0013603 
61. Hachana M, Amara K, Ziadi S, Romdhane E, Gacem RB, Trimeche M. 
Investigation of Epstein-Barr virus in breast carcinomas in Tunisia. Pathol 
Res Pract (2011) 207:695–700. doi:10.1016/j.prp.2011.09.007 
62. Glenn WK, Heng B, Delprado W, Iacopetta B, Whitaker NJ, Lawson JS. 
Epstein-Barr virus, human papillomavirus and mouse mammary tumour 
virus as multiple viruses in breast cancer. PLoS One (2012) 7:e48788. 
doi:10.1371/journal.pone.0048788 
63. Zekri AR, Bahnassy AA, Mohamed WS, El-Kassem FA, El-Khalidi SJ, 
Hafez MM, et al. Epstein-Barr virus and breast cancer: epidemiological and 
molecular study on Egyptian and Iraqi women. J Egypt Natl Canc Inst (2012) 
24:123–31. doi:10.1016/j.jnci.2012.06.001 
64. Aboulkassim T, Yasmeen A, Akil N, Batist G, Al Moustafa AE. Incidence of 
Epstein-Barr virus in Syrian women with breast cancer: a tissue microarray 
study. Hum Vaccin Immunother (2015) 11:951–5. doi:10.1080/21645515.2015. 
1009342 
65. Ghosh SK, Perrine SP, Faller DV. Advances in virus-directed therapeutics 
against Epstein-Barr virus-associated malignancies. Adv Virol (2012) 
2012:509296. doi:10.1155/2012/509296 
66. Nakanishi Y, Wakisaka N, Kondo S, Endo K, Sugimoto H, Hatano M, et al. 
Progression of understanding for the role of Epstein-Barr virus and manage-
ment of nasopharyngeal carcinoma. Cancer Metastasis Rev (2017) 36:435–47. 
doi:10.1007/s10555-017-9693-x 
67. She Y, Nong X, Zhang M, Wang M. Epstein-Barr virus infection and oral 
squamous cell carcinoma risk: a meta-analysis. PLoS One (2017) 12:e0186860. 
doi:10.1371/journal.pone.0186860 
68. Whitaker NJ, Glenn WK, Sahrudin A, Orde MM, Delprado W, Lawson JS. 
Human papillomavirus and Epstein Barr virus in prostate cancer: koilocytes 
indicate potential oncogenic influences of human papillomavirus in prostate 
cancer. Prostate (2013) 73:236–41. doi:10.1002/pros.22562 
69. Al Moustafa AE, Al-Antary N, Aboulkassim T, Akil N, Batist G, Yasmeen A. 
Co-prevalence of Epstein-Barr virus and high-risk human papillomaviruses 
in Syrian women with breast cancer. Hum Vaccin Immunother (2016) 
12:1936–9. doi:10.1080/21645515.2016.1139255 
10
Akhtar et al. EBV in Gliomas
Frontiers in Oncology | www.frontiersin.org April 2018 | Volume 8 | Article 123
70. Mozaffari HR, Ramezani M, Janbakhsh A, Sadeghi M. Malignant salivary 
gland tumors and Epstein-Barr virus (EBV) infection: a systematic review 
and meta-analysis. Asian Pac J Cancer Prev (2017) 18:1201–6. doi:10.22034/
APJCP.2017.18.5.1201
71. Khalil M, Enzinger C, Wallner-Blazek M, Scarpatetti M, Barth A, Horn S, 
et al. Epstein-Barr virus encephalitis presenting with a tumor-like lesion in 
an immunosuppressed transplant recipient. J Neurovirol (2008) 14:574–8. 
doi:10.1080/13550280802345715 
72. Fujimoto H, Asaoka K, Imaizumi T, Ayabe M, Shoji H, Kaji M. Epstein-Barr 
virus infections of the central nervous system. Intern Med (2003) 42:33–40. 
doi:10.2169/internalmedicine.42.33 
73. Gasque P, Chan P, Mauger C, Schouft MT, Singhrao S, Dierich MP, et  al. 
Identification and characterization of complement C3 receptors on human 
astrocytes. J Immunol (1996) 156:2247–55. 
74. Menet A, Speth C, Larcher C, Prodinger WM, Schwendinger MG, Chan P, 
et al. Epstein-Barr virus infection of human astrocyte cell lines. J Virol (1999) 
73:7722–33. 
75. Sugita Y, Muta H, Ohshima K, Morioka M, Tsukamoto Y, Takahashi H, 
et  al. Primary central nervous system lymphomas and related diseases: 
pathological characteristics and discussion of the differential diagnosis. 
Neuropathology (2016) 36:313–24. doi:10.1111/neup.12276 
76. Wrensch M, Weinberg A, Wiencke J, Miike R, Barger G, Kelsey K. Prevalence 
of antibodies to four herpesviruses among adults with glioma and controls. 
Am J Epidemiol (2001) 154:161–5. doi:10.1093/aje/154.2.161 
77. Poltermann S, Schlehofer B, Steindorf K, Schnitzler P, Geletneky K, Schlehofer JR. 
Lack of association of herpesviruses with brain tumors. J Neurovirol (2006) 
12:90–9. doi:10.1080/13550280600654573 
78. Zavala-Vega S, Castro-Escarpulli G, Hernandez-Santos H, Salinas-Lara C, 
Palma I, Mejia-Arangure JM, et al. An overview of the infection of CMV, 
HSV 1/2 and EBV in Mexican patients with glioblastoma multiforme. 
Pathol Res Pract (2017) 213:271–6. doi:10.1016/j.prp.2016.12.006 
79. Fonseca RF, Rosas SL, Oliveira JA, Teixeira A, Alves G, Carvalho Mda G. 
Frequency of Epstein-Barr virus DNA sequences in human gliomas. Sao 
Paulo Med J (2015) 133:51–4. doi:10.1590/1516-3180.2013.1912814 
80. Neves AM, Thompson G, Carvalheira J, Trindade JC, Rueff J, Caetano JM, 
et al. Detection and quantitative analysis of human herpesvirus in pilocytic 
astrocytoma. Brain Res (2008) 1221:108–14. doi:10.1016/j.brainres.2008. 
05.009 
81. Cimino PJ, Zhao G, Wang D, Sehn JK, Lewis JS Jr, Duncavage EJ. Detection 
of viral pathogens in high grade gliomas from unmapped next- 
generation sequencing data. Exp Mol Pathol (2014) 96:310–5. doi:10.1016/j.
yexmp.2014.03.010 
82. Cosset E, Petty TJ, Dutoit V, Cordey S, Padioleau I, Otten-Hernandez P, 
et al. Comprehensive metagenomic analysis of glioblastoma reveals absence 
of known virus despite antiviral-like type I interferon gene response. Int 
J Cancer (2014) 135:1381–9. doi:10.1002/ijc.28670 
83. Khoury JD, Tannir NM, Williams MD, Chen Y, Yao H, Zhang J, et al. Landscape 
of DNA virus associations across human malignant cancers: analysis of 3,775 
cases using RNA-Seq. J Virol (2013) 87:8916–26. doi:10.1128/JVI.00340-13 
84. Hashida Y, Taniguchi A, Yawata T, Hosokawa S, Murakami M, Hiroi M, 
et al. Prevalence of human cytomegalovirus, polyomaviruses, and oncogenic 
viruses in glioblastoma among Japanese subjects. Infect Agent Cancer (2015) 
10:3. doi:10.1186/1750-9378-10-3 
85. Lehrer S. Cytomegalovirus infection in early childhood may be protective 
against glioblastoma multiforme, while later infection is a risk factor. Med 
Hypotheses (2012) 78:657–8. doi:10.1016/j.mehy.2012.02.003 
86. Goodwin S, Mcpherson JD, Mccombie WR. Coming of age: ten years of 
next-generation sequencing technologies. Nat Rev Genet (2016) 17:333–51. 
doi:10.1038/nrg.2016.49 
87. Yohe S, Thyagarajan B. Review of clinical next-generation sequencing. 
Arch Pathol Lab Med (2017) 141:1544–57. doi:10.5858/arpa.2016-0501-RA 
88. Cao Y, Fanning S, Proos S, Jordan K, Srikumar S. A review on the applications 
of next generation sequencing technologies as applied to food-related micro-
biome studies. Front Microbiol (2017) 8:1829. doi:10.3389/fmicb.2017.01829 
89. Gill BJ, Pisapia DJ, Malone HR, Goldstein H, Lei L, Sonabend A, et  al. 
MRI-localized biopsies reveal subtype-specific differences in molecular and 
cellular composition at the margins of glioblastoma. Proc Natl Acad Sci U S A 
(2014) 111:12550–5. doi:10.1073/pnas.1405839111 
90. Vidone M, Alessandrini F, Marucci G, Farnedi A, De Biase D, Ricceri F, et al. 
Evidence of association of human papillomavirus with prognosis worsening 
in glioblastoma multiforme. Neuro Oncol (2014) 16:298–302. doi:10.1093/
neuonc/not140 
91. Saddawi-Konefka R, Crawford JR. Chronic viral infection and primary 
central nervous system malignancy. J Neuroimmune Pharmacol (2010) 
5:387–403. doi:10.1007/s11481-010-9204-0 
92. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell 
control in early events in carcinogenesis. J Natl Cancer Inst (2000) 92:690–8. 
doi:10.1093/jnci/92.9.690 
93. Coghill AE, Hildesheim A. Epstein-Barr virus antibodies and the risk of 
associated malignancies: review of the literature. Am J Epidemiol (2014) 
180:687–95. doi:10.1093/aje/kwu176 
94. Shumilov A, Tsai MH, Schlosser YT, Kratz AS, Bernhardt K, Fink S, et al. 
Epstein-Barr virus particles induce centrosome amplification and chromo-
somal instability. Nat Commun (2017) 8:14257. doi:10.1038/ncomms14257 
95. Soderberg-Naucler C, Rahbar A, Stragliotto G. Survival in patients with 
glioblastoma receiving valganciclovir. N Engl J Med (2013) 369:985–6. 
doi:10.1056/NEJMc1302145 
96. Shih WL, Fang CT, Chen PJ. Anti-viral treatment and cancer control. Recent 
Results Cancer Res (2014) 193:269–90. doi:10.1007/978-3-642-38965-8_14 
97. Jacobson CA, Abramson JS. HIV-associated Hodgkin’s lymphoma: prog-
nosis and therapy in the era of cART. Adv Hematol (2012) 2012:507257. 
doi:10.1155/2012/507257 
98. Vishnu P, Aboulafia DM. AIDS-related non-Hodgkin’s lymphoma in the era 
of highly active antiretroviral therapy. Adv Hematol (2012) 2012:485943. 
doi:10.1155/2012/485943 
99. Zakaria Z, Fenton E, Khalil A, Sattar MT, Molnar P. Stupp-treated glioblas-
toma accompanied by EBV-positive primary CNS lymphoma. Br J Neurosurg 
(2014) 28:287–9. doi:10.3109/02688697.2013.829554 
100. Cohen JI. Epstein-Barr virus vaccines. Clin Transl Immunology (2015) 4:e32. 
doi:10.1038/cti.2014.27 
101. Hui EP, Taylor GS, Jia H, Ma BB, Chan SL, Ho R, et al. Phase I trial of recom-
binant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens 
in nasopharyngeal carcinoma patients. Cancer Res (2013) 73:1676–88. 
doi:10.1158/0008-5472.CAN-12-2448 
102. Ruiss R, Jochum S, Wanner G, Reisbach G, Hammerschmidt W, Zeidler R. 
A virus-like particle-based Epstein-Barr virus vaccine. J Virol (2011) 85: 
13105–13. doi:10.1128/JVI.05598-11 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2018 Akhtar, Vranic, Cyprian and Al Moustafa. This is an open-access 
article distributed under the terms of the Creative Commons Attribution License 
(CC BY). The use, distribution or reproduction in other forums is permitted, provided 
the original author(s) and the copyright owner are credited and that the original 
publication in this journal is cited, in accordance with accepted academic practice. No 
use, distribution or reproduction is permitted which does not comply with these terms.
